Gladstone Institutional Advisory LLC Cellectis S.A. Transaction History

Gladstone Institutional Advisory LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$8.01 - $12.84 $102,327 - $164,031	-12,775 Closed	0 $0
Q3 2021 Jan 27, 2023	BUY	$11.94 - $16.09 $13,539 - $18,246	1,134 Added 9.74%	12,775 $161,000
Q3 2021 Nov 15, 2021	BUY	$11.94 - $16.09 $13,539 - $18,246	1,134 Added 9.74%	12,775 $161,000
Q2 2021 Jan 27, 2023	BUY	$14.36 - $20.93 $167,164 - $243,646	11,641 New	11,641 $180,000
Q2 2021 Aug 13, 2021	BUY	$14.36 - $20.93 $167,164 - $243,646	11,641 New	11,641 $180,000

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $86M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Gladstone Institutional Advisory LLC, based on Form 13F filings with the SEC.

Stay updated on Gladstone Institutional Advisory LLC with notifications on news.